ClinicalTrials.Veeva

Menu

Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar Extraction

Pierre Fabre logo

Pierre Fabre

Status and phase

Completed
Phase 4

Conditions

Alveolar Osteitis

Treatments

Drug: Placebo
Drug: DC071

Study type

Interventional

Funder types

Industry

Identifiers

NCT02382809
2014-004682-24 (EudraCT Number)
DC0071 BB 4 05

Details and patient eligibility

About

The purpose of this study is to demonstrate the efficacy of 0.2 % digluconate chlorhexidine mouthwash in the prevention of alveolar osteitis following third molar extraction and to evaluate the safety and local tolerability.

Enrollment

414 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female over 18 years old
  • Subject needing to undergo extraction of one impacted mandibular third molar
  • For woman of childbearing potential and woman in post menopausal period under hormonal substitution treatment, she must accept to plan the extraction of the impacted mandibular third molar only during the last week of the menstrual cycle.
  • Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)

Exclusion criteria

  • Existence or history of parotid gland disorders
  • Acute or history of recent acute pericoronitis at any tooth
  • Extraction of more than 1 third molar in the same surgical procedure
  • Subject at high risk of bacterial endocarditis (prosthetic heart valve, history of bacterial endocarditis, congenital cyanogenic heart disease)
  • Coagulation or haemostatic disorder or use of anticoagulants
  • Hypersensitivity to chlorhexidine or any of the excipients;
  • Hypersensitivity to any anesthetic agent;
  • Hypersensitivity to corticosteroids, analgesics including opioid drugs used for post-surgery pain relief
  • Intake of systemic vasodilator or vasoconstrictor
  • Intake of systemic or local (in the mouth) antibiotics within 7 days before Day 1 and/or any pre- or post-operative antibiotic prophylaxis planned to be prescribed during the study;
  • Use of any antiseptic mouthwash within 7 days before Day -1
  • Regular heavy smokers (more than 20 cigarettes per day)
  • Is pregnant or in post-partum period or a nursing mother

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

414 participants in 2 patient groups, including a placebo group

DC071 (0.2% chlorhexidine digluconate)
Experimental group
Treatment:
Drug: DC071
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

18

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems